Reneo Pharmaceuticals, Inc entered into a Subscription Agreement of common shares for a gross proceeds $65,000,000 on May 10, 2024.The transaction includes participation from OnKure, Inc, RADIATE MERGER SUB II, LLC and Radiate Merger Sub I, Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.645 USD | -1.50% | -1.50% | +2.81% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.81% | 55.81M | |
+48.45% | 57.87B | |
+41.65% | 40.25B | |
-7.09% | 39.94B | |
-5.96% | 28.54B | |
+12.25% | 26.4B | |
-20.20% | 19.33B | |
+29.90% | 12.4B | |
-0.68% | 12.23B | |
+24.22% | 12.2B |
- Stock Market
- Equities
- RPHM Stock
- News Reneo Pharmaceuticals, Inc.
- Reneo Pharmaceuticals, Inc. announced that it expects to receive $65 million in funding from OnKure, Inc., RADIATE MERGER SUB II, LLC, Radiate Merger Sub I, Inc